CDER unveils 30 new planned guidance documents in 2022 agenda
Posted 07 February 2022 | By Jeff Craven About one-third of the guidance documents in the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER)’s 2022 guidance agenda are new, with some recognizable documents from previous years making a reappearance. CDER’s guidance agenda, which is widely understood…